PqsR inverse agonists

US11883387B2 · kind B2 · utility

Assignee

• Helmholtz-Zentrum Für Infektionsforschung GmbH · DE

Inventors

• Ahmed S. A. Ahmed · Braunschweig, DE
• Martin Empting · Mühlheim am Main, DE
• Mostafa Hamed · Braunschweig, DE
• Rolf Hartmann · Saarburg, DE
• Jörg Haupenthal · Braunschweig, DE
• Thomas Hesterkamp · Hamburg, DE
• Ahmed Kamal · Hyderabad, IN
• Christine K. Maurer · Homburg, DE
• Teresa Röhrig · Braunschweig, DE
• Christian Schütz · Hille, DE
• Samir Yahiaoui · Braunschweig, DE
• Michael Zender · Braunschweig, DE

Key dates

• Filing date: Jul 3, 2019
• Grant date: Jan 30, 2024
• Expiry date: Apr 23, 2040

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D471/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to a compound according to general formula (I), which acts as an inhibitor of PqsR (the currently only known receptor for the Pseudomonas Quinolone Signal (PQS)); to a pharmaceutical composition containing one or more of the compound(s) of the invention; to a combination preparation containing at least one compound of the invention and at least one further active pharmaceutical ingredient; and to uses of said compound(s), including the use as a medicament, e.g. the use in the treatment or prophylaxis of a bacterial infection, especially a Pseudomonas aeruginosa or Burkholderia infection.